These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24870797)

  • 1. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
    Gunduz S; Mutlu H; Uysal M; Coskun HS; Bozcuk H
    Asian Pac J Cancer Prev; 2014; 15(8):3801-4. PubMed ID: 24870797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 4. Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
    Chrom P; Stec R; Semeniuk-Wojtas A; Bodnar L; Spencer NJ; Szczylik C
    Clin Genitourin Cancer; 2016 Oct; 14(5):457-464. PubMed ID: 26980234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy.
    Cai W; Kong W; Dong B; Zhang J; Chen Y; Xue W; Huang Y; Zhou L; Huang J
    Clin Genitourin Cancer; 2017 Jun; 15(3):e437-e446. PubMed ID: 28188047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
    Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
    J Urol; 2016 Nov; 196(5):1363-1370. PubMed ID: 27288695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma.
    Cetin B; Afsar B; Deger SM; Gonul II; Gumusay O; Ozet A; Benekli M; Coskun U; Buyukberber S
    Int Urol Nephrol; 2014 Jun; 46(6):1081-7. PubMed ID: 24307427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
    Ishihara H; Yagisawa T; Kondo T; Omae K; Takagi T; Iizuka J; Kobayashi H; Tanabe K
    Int J Clin Oncol; 2017 Feb; 22(1):126-135. PubMed ID: 27549785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
    J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma.
    Dirican A; Kucukzeybek Y; Somali I; Erten C; Demir L; Can A; Bahriye Payzin K; Vedat Bayoglu I; Akyol M; Koseoglu M; Alacacioglu A; Oktay Tarhan M
    J BUON; 2013; 18(2):413-9. PubMed ID: 23818354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
    Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
    Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
    Wang HK; Wan FN; Gu WJ; Zhu Y; Dai B; Shi GH; Zhang HL; Ye DW
    Oncotarget; 2016 Oct; 7(42):68943-68953. PubMed ID: 27661105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
    Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
    BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
    Kwon T; Lee JL; You D; Jeong IG; Song C; Ahn H; Kim CS; Hong JH
    J Surg Oncol; 2014 Aug; 110(2):145-50. PubMed ID: 24706355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?
    Cetin B; Berk V; Kaplan MA; Afsar B; Tufan G; Ozkan M; Isikdogan A; Benekli M; Coskun U; Buyukberber S
    Clin Genitourin Cancer; 2013 Jun; 11(2):141-8. PubMed ID: 23083797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Leung HW; Chan AL
    Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.